Affymax Wins Approval of Drug for Anemic Kidney Patients
This article is for subscribers only.
Affymax Inc. won U.S. approval for Omontys, a competitor to Amgen Inc.’s anemia treatments that have been the only options for patients with loss of kidney function for more than 20 years.
The Food and Drug Administration cleared Omontys, known as peginesatide, for patients with chronic kidney disease on dialysis, the agency said today in a statement. The drug will be Palo Alto, California-based Affymax’s first marketed product.